Viking Therapeutics, Inc. (FRA:1VT)
Germany
· Delayed Price · Currency is EUR | Market Cap | 3.74B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -202.33M |
| Shares Out | n/a |
| EPS (ttm) | -1.81 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 462 |
| Open | 33.12 |
| Previous Close | 29.85 |
| Day's Range | 33.11 - 33.50 |
| 52-Week Range | 16.40 - 49.61 |
| Beta | n/a |
| RSI | 46.62 |
| Earnings Date | Feb 5, 2026 |
About Viking Therapeutics
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company’s lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II ... [Read more]
News
VKTX Stock Rises 34% in Three Months: Here's What You Should Know
Viking Therapeutics' shares jump 34% as rapid VK2735 trial enrollment boosts optimism amid intensifying interest in obesity treatments.
Wall Street Analysts Think Viking Therapeutics (VKTX) Is a Good Investment: Is It?
According to the average brokerage recommendation (ABR), one should invest in Viking Therapeutics (VKTX). It is debatable whether this highly sought-after metric is effective because Wall Street analy...
Prediction: This Undervalued Stock Could Compete With Novo Nordisk by 2029
Viking Therapeutics could enter the weight loss market by 2029. The company's leading candidate looks very promising.
Viking Therapeutics to Participate at the Piper Sandler 37th Annual Healthcare Conference
SAN DIEGO , Nov. 25, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic an...
2 Healthcare Stocks for Beginner Investors With a 20-Year Time Horizon
If you want to invest in top healthcare stocks, both of these are worth consideration. Pfizer is moving past the pandemic era, and tremendous growth could be ahead.
3 Weight-Loss Drug Stocks To Consider For 2026
The global weight loss drug market, perhaps ironically, is growing like gangbusters these days. Globally, it's set to expand from $15 billion in 2024 to $150 billion by 2035, according to Morgan Stanl...
Viking Therapeutics (VKTX) Up 1% Since Last Earnings Report: Can It Continue?
Viking Therapeutics (VKTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
3 Mid-Cap Growth Stocks That Have Mammoth Long-Term Potential
Mid-cap stocks can come with risks, but also a ton of upside in the long run. The stocks listed here offer exciting growth opportunities across multiple industries.
VKTX Completes Enrollment in First Late-Stage Study on Obesity Drug
Viking Therapeutics completes enrollment in its phase III VANQUISH-1 obesity study, surpassing targets and marking rapid progress for its VK2735 program.
Viking Therapeutics, Up 62% Since August, Lingers In Buy Zone On An Obesity Win
Viking Therapeutics stock yo-yoed Wednesday after the company said it overenrolled one of its final-phase studies for its weight-loss shot.
Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.
Eli Lilly has advanced in the triple-digits over three years, thanks to its weight loss drug portfolio. The following two biotech companies, due to the potential of their late-stage candidates, also c...
Viking Therapeutics (VKTX) Completes Enrollment for Key Phase 3 Trial
Viking Therapeutics (VKTX) Completes Enrollment for Key Phase 3 Trial
Viking Therapeutics, Inc. (VKTX) Presents at Jefferies London Healthcare Conference 2025 Transcript
Viking Therapeutics, Inc. (VKTX) Jefferies London Healthcare Conference 2025 November 19, 2025 3:00 AM ESTCompany ParticipantsBrian Lian - President, CEO...
Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-1 Trial of VK2735
78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity Enrollment Completed Ahead of Schedule and Above Target Size, Indicating Strong Interest in VK2735 SAN DIEGO , Nov. 19, 2025 /PRNews...
5AM Venture Just Dumped Its Viking Stake—Smart Call or Missed Opportunity?
One major biotech investor just walked away from Viking Therapeutics. Here’s what the move may—and may not—mean for the company’s clinical-stage future.
2 No-Brainer Healthcare Stocks to Buy Now
Pfizer's acquisition of obesity drugmaker Metsera positions the pharmaceutical giant to compete in a market expected to reach $130 billion by 2030. Viking Therapeutics has both injectable and oral ver...
Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views?
According to the average brokerage recommendation (ABR), one should invest in Viking Therapeutics (VKTX). It is debatable whether this highly sought-after metric is effective because Wall Street analy...
Viking Therapeutics (VKTX): Canaccord Genuity Raises Price Target | VKTX Stock News
Viking Therapeutics (VKTX): Canaccord Genuity Raises Price Target | VKTX Stock News
AMD, Oklo, AppLovin Corp, Viking Therapeutics And Novo Nordisk: Why These 5 Stocks Are On Investors' Radars Today
Major U.S. indices closed mixed on Tuesday, with the Dow Jones Industrial Average climbing 1.2% to 47,927.96 and the S&P 500 inching up 0.2% to 6,846.61, while the tech-heavy Nasdaq slipped 0.25% to 2...
2 Monster Stocks in the Making
Viking Therapeutics is developing innovative medicines in a fast-growing area. Axsome Therapeutics is generating strong sales, and solid regulatory progress could improve things.
Is There a Future for Viking Therapeutics?
Key PointsViking has initiated an exciting new phase 1 study combining an oral and subcutaneous formulation of a weight loss drug.
Is There a Future for Viking Therapeutics?
Viking has initiated an exciting new phase 1 study combining an oral and subcutaneous formulation of a weight loss drug. The phase 1 trial results are expected next year, with the Phase 3 (subcutaneou...
Spotlight on Viking Therapeutics: Analyzing the Surge in Options Activity
Investors with a lot of money to spend have taken a bullish stance on Viking Therapeutics (NASDAQ: VKTX). And retail traders should know. We noticed this today when the trades showed up on publicly a...
Viking Therapeutics (VKTX) Reports Positive Phase 2 Results for VK2735
Viking Therapeutics (VKTX) Reports Positive Phase 2 Results for VK2735
Interesting VKTX Put And Call Options For December 26th
Investors in Viking Therapeutics Inc (Symbol: VKTX) saw new options become available today, for the December 26th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down th...